NO328594B1 - Anvendelse av et aminoglukosidantibiotikum for fremstilling av et preparat for behandling av kronisk bronkitt - Google Patents
Anvendelse av et aminoglukosidantibiotikum for fremstilling av et preparat for behandling av kronisk bronkitt Download PDFInfo
- Publication number
- NO328594B1 NO328594B1 NO20012978A NO20012978A NO328594B1 NO 328594 B1 NO328594 B1 NO 328594B1 NO 20012978 A NO20012978 A NO 20012978A NO 20012978 A NO20012978 A NO 20012978A NO 328594 B1 NO328594 B1 NO 328594B1
- Authority
- NO
- Norway
- Prior art keywords
- patients
- tobramycin
- antibiotic
- aeruginosa
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 49
- 238000011282 treatment Methods 0.000 title claims description 48
- 230000003115 biocidal effect Effects 0.000 title claims description 35
- 206010006458 Bronchitis chronic Diseases 0.000 title claims description 13
- 206010006451 bronchitis Diseases 0.000 title claims description 13
- 208000007451 chronic bronchitis Diseases 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 7
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 79
- 229960000707 tobramycin Drugs 0.000 claims description 77
- 238000009472 formulation Methods 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 35
- 239000000443 aerosol Substances 0.000 claims description 33
- 239000006199 nebulizer Substances 0.000 claims description 32
- 229940071648 metered dose inhaler Drugs 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
- 229940112141 dry powder inhaler Drugs 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229960000808 netilmicin Drugs 0.000 claims description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 description 44
- 208000024794 sputum Diseases 0.000 description 44
- 210000003802 sputum Anatomy 0.000 description 44
- 239000003814 drug Substances 0.000 description 40
- 229940079593 drug Drugs 0.000 description 39
- 229940068196 placebo Drugs 0.000 description 37
- 239000000902 placebo Substances 0.000 description 37
- 201000009267 bronchiectasis Diseases 0.000 description 28
- 201000003883 Cystic fibrosis Diseases 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 230000008859 change Effects 0.000 description 16
- 239000003242 anti bacterial agent Substances 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 229940088710 antibiotic agent Drugs 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 101150034459 Parpbp gene Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000002906 microbiologic effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000002345 respiratory system Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000000227 grinding Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 210000003123 bronchiole Anatomy 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 208000032536 Pseudomonas Infections Diseases 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 238000012387 aerosolization Methods 0.000 description 4
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 229940047650 haemophilus influenzae Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013125 spirometry Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229940035289 tobi Drugs 0.000 description 2
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- XCLJRCAJSCMIND-JCTYMORFSA-N (9S)-erythromycyclamine Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)[C@@H](N)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XCLJRCAJSCMIND-JCTYMORFSA-N 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 208000025678 Ciliary Motility disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 206010035623 Pleuritic pain Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000187178 Streptoalloteichus tenebrarius Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000038009 orphan disease Diseases 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11298498P | 1998-12-17 | 1998-12-17 | |
| PCT/US1999/030234 WO2000035461A1 (fr) | 1998-12-17 | 1999-12-17 | Procede de traitement de la bronchite chronique severe (bronchiectasie) avec un antibiotique en aerosol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012978D0 NO20012978D0 (no) | 2001-06-15 |
| NO20012978L NO20012978L (no) | 2001-08-15 |
| NO328594B1 true NO328594B1 (no) | 2010-03-29 |
Family
ID=22346930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012978A NO328594B1 (no) | 1998-12-17 | 2001-06-15 | Anvendelse av et aminoglukosidantibiotikum for fremstilling av et preparat for behandling av kronisk bronkitt |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6387886B1 (fr) |
| EP (1) | EP1161247A4 (fr) |
| JP (1) | JP2002532430A (fr) |
| CN (1) | CN1348377A (fr) |
| AU (1) | AU778797B2 (fr) |
| BR (1) | BR9916296A (fr) |
| CA (1) | CA2355775A1 (fr) |
| CH (1) | CH693763A5 (fr) |
| CZ (1) | CZ20012147A3 (fr) |
| HK (1) | HK1043732A1 (fr) |
| HU (1) | HUP0105226A3 (fr) |
| NO (1) | NO328594B1 (fr) |
| PL (1) | PL348812A1 (fr) |
| SI (1) | SI20959A (fr) |
| WO (1) | WO2000035461A1 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
| US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US8336545B2 (en) | 2000-05-05 | 2012-12-25 | Novartis Pharma Ag | Methods and systems for operating an aerosol generator |
| US7971588B2 (en) | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| EP1280520B2 (fr) | 2000-05-10 | 2018-03-21 | Novartis AG | Poudres a base de phospholipides permettant de distribuer un medicament |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| AU2002231244B2 (en) | 2000-12-27 | 2006-06-29 | Gilead Sciences, Inc. | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| EP1598059A1 (fr) * | 2001-05-18 | 2005-11-23 | Chiron Corporation | Méthodes et formulations en doses unitaires pour l'administration d'aminoglycosides par inhalation |
| AU2007202942B2 (en) * | 2001-05-18 | 2010-05-27 | Novartis Ag | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
| PT1320355E (pt) * | 2001-05-18 | 2006-08-31 | Chiron Corp | Sistema para administracao de uma formulacao de tobramicina |
| US20040022740A1 (en) * | 2001-07-10 | 2004-02-05 | Baker William R. | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| TWI324518B (en) * | 2001-12-19 | 2010-05-11 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| US7607436B2 (en) * | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
| US8245708B2 (en) * | 2002-05-07 | 2012-08-21 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
| AU2003238846A1 (en) * | 2002-05-31 | 2003-12-19 | Childrens Hospital And Regional Medical Center | Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function |
| US6966649B2 (en) * | 2002-08-12 | 2005-11-22 | John H Shadduck | Adaptive optic lens system and method of use |
| US20070128124A1 (en) * | 2002-09-12 | 2007-06-07 | Kraus Carl N | Aerosolized capreomycin for inhibition of pulmonary tuberculosis |
| EP1560540A4 (fr) * | 2002-10-18 | 2008-03-19 | Molichem Medicines Inc | Methodes de traitement de la maladie de l'oeil sec avec des lantibiotiques |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| EP2823820B1 (fr) * | 2002-10-29 | 2018-06-06 | Insmed Incorporated | Liposomes contenant un aminoglycoside pour le traitement d'infections pulmonaires |
| US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| DK1673074T3 (da) * | 2003-10-15 | 2007-05-07 | Pari Gmbh | Flydende præparat, indeholdende tobramycin |
| WO2005107787A1 (fr) * | 2004-05-06 | 2005-11-17 | Molichem Medicines, Inc. | Traitement de maladies et troubles associes aux membranes au moyen de compositions contenant des lantibiotiques |
| US7479481B2 (en) * | 2004-05-06 | 2009-01-20 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
| PT2266534E (pt) | 2004-05-17 | 2012-10-09 | Gilead Sciences Inc | Combinação fosfomicina/aminoglicósido num aerossol para o tratamento de infecções respiratórias devidas a bactérias |
| DK1765288T3 (da) * | 2004-06-18 | 2013-02-11 | Novartis Ag | Tobramycinpræparater til behandling af endobronchiale infektioner |
| BRPI0616642A2 (pt) * | 2005-09-29 | 2011-06-28 | Nektar Therapeutics | formulações de antibióticos, doses unitárias, kits e métodos |
| AU2013206401B2 (en) * | 2005-09-29 | 2016-06-23 | Novartis Ag | Antibiotic formulations, unit doses, kits, and methods |
| AU2006322076C1 (en) | 2005-12-08 | 2013-11-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| EP2012750B1 (fr) * | 2006-04-06 | 2018-02-21 | Insmed Incorporated | Procédés d'encapsulation liposomale induite par coacervation et formulations associées |
| JP2008199905A (ja) * | 2007-02-16 | 2008-09-04 | Snow Brand Milk Prod Co Ltd | 乳酸菌生残性向上剤 |
| US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US8551534B2 (en) * | 2007-10-10 | 2013-10-08 | Parion Sciences, Inc. | Inhaled hypertonic saline delivered by a heated nasal cannula |
| EP2098219A1 (fr) | 2008-03-05 | 2009-09-09 | PARI Pharma GmbH | Compositions de macrolide ayant un goût et une stabilité améliorés |
| MX2011000405A (es) * | 2008-07-18 | 2011-03-04 | Prosonix Ltd | Proceso para mejorar la cristalinidad. |
| BR112013000921A2 (pt) * | 2010-07-12 | 2016-05-17 | Xellia Pharmaceuticals Aps | tratamento de infecções pulmonares pela administração de tobramicina por aerolização |
| US8689439B2 (en) | 2010-08-06 | 2014-04-08 | Abbott Laboratories | Method for forming a tube for use with a pump delivery system |
| US8377001B2 (en) | 2010-10-01 | 2013-02-19 | Abbott Laboratories | Feeding set for a peristaltic pump system |
| US8377000B2 (en) | 2010-10-01 | 2013-02-19 | Abbott Laboratories | Enteral feeding apparatus having a feeding set |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| JP6219271B2 (ja) | 2011-06-07 | 2017-10-25 | パリオン・サイエンシィズ・インコーポレーテッド | 治療の方法 |
| WO2013010041A1 (fr) | 2011-07-12 | 2013-01-17 | Cardeas Pharma Inc. | Formulations de combinaisons d'amikacine et de fosfomycine et procédés et systèmes pour le traitement de la pneumonie associée au ventilateur (pav) et de la trachéobronchite associée au ventilateur (tav) |
| US8826904B2 (en) | 2011-07-12 | 2014-09-09 | Cardeas Pharma Corporation | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis |
| KR102092361B1 (ko) | 2012-05-21 | 2020-03-23 | 인스메드 인코포레이티드 | 폐 감염을 치료하기 위한 시스템 |
| CN102949379B (zh) * | 2012-11-14 | 2014-11-05 | 中山大学 | 硫酸奈替米星吸入粉雾剂及其制备方法 |
| MX2015006681A (es) | 2012-11-29 | 2016-04-06 | Insmed Inc | Formulaciones de vancomicina estabilizadas. |
| CN104510726A (zh) * | 2013-09-27 | 2015-04-15 | 张金华 | 一种用于清洁呼吸道系统的食盐干粉吸入剂 |
| ES2981634T3 (es) | 2014-05-15 | 2024-10-09 | Insmed Incorporated | Métodos para tratar infecciones micobacterianas pulmonares no tuberculosas |
| EP3773505A4 (fr) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | Procédés pour la fabrication continue de produits médicamenteux liposomaux |
| CN109172965B (zh) * | 2018-10-24 | 2024-09-13 | 威海盛洁医疗科技有限公司 | 一种雾化颗粒大小可调节的雾化杯 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| US5512269A (en) * | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
| US5522385A (en) * | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5508269A (en) * | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
-
1999
- 1999-12-17 HU HU0105226A patent/HUP0105226A3/hu not_active Application Discontinuation
- 1999-12-17 JP JP2000587781A patent/JP2002532430A/ja not_active Withdrawn
- 1999-12-17 WO PCT/US1999/030234 patent/WO2000035461A1/fr not_active Application Discontinuation
- 1999-12-17 CA CA002355775A patent/CA2355775A1/fr not_active Abandoned
- 1999-12-17 SI SI9920098A patent/SI20959A/sl not_active IP Right Cessation
- 1999-12-17 US US09/868,299 patent/US6387886B1/en not_active Expired - Lifetime
- 1999-12-17 EP EP99967420A patent/EP1161247A4/fr not_active Withdrawn
- 1999-12-17 PL PL99348812A patent/PL348812A1/xx not_active Application Discontinuation
- 1999-12-17 CZ CZ20012147A patent/CZ20012147A3/cs unknown
- 1999-12-17 BR BR9916296-2A patent/BR9916296A/pt not_active Application Discontinuation
- 1999-12-17 CH CH01437/01A patent/CH693763A5/de not_active IP Right Cessation
- 1999-12-17 AU AU23701/00A patent/AU778797B2/en not_active Ceased
- 1999-12-17 CN CN99816160A patent/CN1348377A/zh active Pending
-
2001
- 2001-06-15 NO NO20012978A patent/NO328594B1/no not_active IP Right Cessation
-
2002
- 2002-06-11 HK HK02104354.0A patent/HK1043732A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU778797B2 (en) | 2004-12-23 |
| CN1348377A (zh) | 2002-05-08 |
| HK1043732A1 (zh) | 2002-09-27 |
| EP1161247A1 (fr) | 2001-12-12 |
| US6387886B1 (en) | 2002-05-14 |
| JP2002532430A (ja) | 2002-10-02 |
| PL348812A1 (en) | 2002-06-17 |
| HUP0105226A2 (hu) | 2002-04-29 |
| NO20012978L (no) | 2001-08-15 |
| CA2355775A1 (fr) | 2000-06-22 |
| NO20012978D0 (no) | 2001-06-15 |
| AU2370100A (en) | 2000-07-03 |
| HUP0105226A3 (en) | 2003-03-28 |
| BR9916296A (pt) | 2004-06-29 |
| WO2000035461A1 (fr) | 2000-06-22 |
| CH693763A5 (de) | 2004-01-30 |
| SI20959A (sl) | 2003-02-28 |
| EP1161247A4 (fr) | 2002-05-15 |
| CZ20012147A3 (cs) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU778797B2 (en) | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic | |
| US6083922A (en) | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis | |
| AU2002231244B2 (en) | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections | |
| US5508269A (en) | Aminoglycoside formulation for aerosolization | |
| AU2002231244A1 (en) | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections | |
| US20070185076A1 (en) | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial inections | |
| MXPA01006134A (en) | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |